Zydus Lifesciences Limited has secured tentative approval from the United States Food and Drug Administration (USFDA) for its Enzalutamide Tablets, available in 40 mg and 80 mg strengths. This significant approval marks a pivotal moment for the company, expanding its portfolio of cancer treatments and positioning it for a more substantial presence in the global […]
Zydus Lifesciences Limited has achieved a significant milestone in the pharmaceutical industry. The company recently received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg. This approval marks a major victory for Zydus as the capsules, an androgen receptor inhibitor, are critical for treating metastatic castration-resistant prostate […]
Imugene Limited has received a significant boost with the United States Food and Drug Administration (FDA) granting Orphan Drug Designation (ODD) to its experimental therapy, CF33-hNIS (VAXINIA), aimed at treating bile tract cancer. This designation propels Imugene’s clinical-stage oncolytic virotherapy forward, positioning the Sydney-based company as a key player in the development of innovative cancer […]